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Abstract
Background: Illness Management & Recovery (IMR) is a curriculum-based program for people with severe and
persistent mental illness. To date, four randomized controlled trials (RCTs) have been published on it. As these
produced mixed results, we conducted a pilot study to test the feasibility of conducting a new RCT in a Dutch
psychiatric institute. Because our primary objective was to evaluate support for implementing IMR on a broader
scale, we examined participant recruitment, client outcomes, and clients’ and clinicians’ satisfaction. Secondary
objectives were to evaluate fidelity, trainers’ training and supervision, and to explore program duration, dropout,
and client characteristics related to dropout. For reporting, we used the checklist for pilot studies adopted from the
CONSORT Statement.
Methods: This program evaluation included a process-evaluation and an outcome evaluation with a One Group
Pre-Posttest Design (N = 81). Interviews and internal reports were used to monitor participant numbers, program
duration, dropout, and completers’ characteristics. Clients’ and clinicians’ satisfaction and provision of trainers’ training
and supervision were assessed through interviews. Fidelity was assessed on the IMR Fidelity Scale; client outcomes
were assessed on the IMR scale (client and clinician versions) and the Recovery Markers Questionnaire (RMQ).
Results: Eighty-one participants were recruited of 167 people who were assessed for eligibility. Completers and
clinicians were satisfied, and scores for completers improved significantly on the IMR scale (clinician version) (d = 0.84)
and RMQ (d = 0.52), and not significantly on the IMR scale client version (d = 0.41). Mean fidelity was good, but three
groups had only moderate fidelity. Our feasibility criterion for trainers’ education and supervision was partly attained.
Dropout from treatment was 51 %; female participants and people who scored higher on both IMR-scales at baseline
had a significantly lower chance of dropping out. The duration of IMR varied (M = 12.7 months, SD = 2.87).
Conclusions: Results suggested that feasibility of conducting an RCT on IMR was good. Special attention is required to
fidelity, IMR duration, trainers’ education and supervision, and dropout, especially of men. One study limitation was our
inability to conduct follow-up measurements of non-completers.
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Background
Introduction
The aim of Illness Management and Recovery (IMR) is
to provide a structured psychosocial program that helps
individuals to manage the disabling effects of severe and
persistent mental illnesses such as schizophrenia and
bipolar disorders. It is curriculum based. To improve dif-
ferent aspects of illness management, it includes inter-
ventions such as goal-setting, psycho-education, and
coping and social skills training. The overall aim is to
improve illness outcomes and to support subjective and
objective recovery [1]. IMR is based on a review of con-
trolled research on professionally based programs for
helping people to manage their mental illness [2]. It was
developed in the United States [3, 4] and is currently
used in several countries. While its individual compo-
nents are not new in Dutch Mental Health Care, what is
new of this program is to offer these services together as
an integrated package.
A review conducted in 2011 showed that three random-
ized controlled trials (RCTs), three quasi-controlled trials
and three pre-post trials had been conducted on the over-
all IMR program [5]. To date (March 2016), four RCTs
have been published on this program [6–9]. The results
were mixed. The three RCTs that had been published be-
fore the start of our pilot [6–8] differed from each other
with regard to setting, the number of participants and
diagnoses, the length and format of IMR, the trainers’
training and their qualifications, the frequency of supervi-
sion of the trainers, the number and timing of measure-
ments and the fidelity of implementation of IMR [10].
The same three RCTs compared IMR with care as
usual (CAU) [6–8]. On the overall score of the client
version of the Illness Management and Recovery Scale
(IMRS) [11–13], two of them showed significantly posi-
tive results for clients assigned to IMR relative to those
in the control groups; the respective effect sizes were .36
[7] and .29 [8]. The other study found a significant im-
provement only if the analyses were limited to sites with
high IMR fidelity [6]. On the overall score of the clin-
ician version of the IMRS [11–13], all three of these
studies showed significantly positive results for clients
assigned to IMR relative to those in the control groups,
with respective effect sizes of .28 [6], .39 [7] and .34
[5, 8]. Additional significantly positive results for IMR
were found on client-reported knowledge in one study [6],
on client-reported coping in another study [8], on
clinician-reported quality of life in the third study [7], and
on observer-rated psychiatric symptoms in two of these
studies [7, 8]. These results were either not found in the
other RCTs, or the domains in question were not mea-
sured. No significant outcomes were found on objective
outcomes such as medication dosage, employment, or
number of hospitalizations [10]. The fourth, (i.e. later),
RCT by Salyers et al. [9] compared IMR with an active
control group. This measured psychiatric symptoms, qual-
ity of life, illness self-management, patient activation,
medical adherence, perceived recovery, hope, and service
utilization. No significant differences were found between
the outcomes of IMR and those of a problem-solving
group. Seventy-two percent of the participants did not
complete the IMR program. Due to these mixed results,
more research is needed on the outcomes of IMR.
In our main study we aim to study the effects of IMR in
a Dutch context in a randomized multi-centre, single-
blinded, clinical trial intended to compare IMR with treat-
ment as usual for outpatient clients with severe and
persistent mental illness. We will investigate whether IMR
leads to better illness management, fewer symptoms and
fewer relapses, and also to better subjective and objective
recovery. Our study design was inspired by Mueser’s Con-
ceptual Framework for IMR, which is claimed to affect
many aspects of illness management and recovery [1, 10].
We expect the planned RCT to produce positive re-
sults on both of the IMR scales, similar to those found
in the earlier studies that used CAU as a control [6–8]
(see above). We also hope to gain additional information
with regard to symptoms, coping and recovery, on which
the earlier results differed.
The two main differences between our planned RCT
and previous studies are 1.) that we will use various out-
come measures on illness management, illness outcomes
and recovery to provide a thorough measurement of the
effects of IMR; and 2.) by testing our hypotheses, we will
test various associations supposed by Mueser et al. [1] in
their conceptual framework. By testing various compo-
nents of the model, it might thus be said that we will
test the model as a whole.
Rationale for assessing feasibility through piloting
Before deciding whether an RCT could be conducted,
we evaluated the implementation of IMR in a pilot study
intended to explore the feasibility of an RCT and to pro-
vide practical guidelines for the optimal implementation
of IMR in a Dutch setting. Feasibility can be defined as
“the extent to which a practice can be used or carried
out within a setting” [14]. Feasibility studies are pieces of
research done before a main study. They are used to es-
timate important parameters that are needed to design
the main study [15]. Sometimes feasibility studies and
pilot studies are not distinguished from each other [16].
We considered the support base for implementing
IMR on a broader scale to be important to the feasibility
of an RCT, as this would affect the number of partici-
pants who could be recruited for the RCT and because it
would be executed in the same institute. This support
base would be affected by participants’ and clinicians’
satisfaction with IMR and by its perceived effectiveness.
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As the feasibility of such an RCT would also depend on
the quality with which IMR was implemented, we chose to
investigate aspects of implementation on which the earlier
RCTs had differed, such as fidelity, trainers’ education and
supervision, dropout from IMR, and IMR duration.
Our pilot study was designed as a program-evaluation
that included a process evaluation and an outcome
evaluation. As there have recently been calls for in-
creased scientific rigor in pilot and feasibility studies
[17], our reporting of this study is based on “Checklist:
Items to include when reporting a pilot study” [16]
adopted from the CONSORT format [18].
Methods
Participants and setting
In the pilot study we included adult outpatient clients
aged between 18 and 65 with severe and persistent men-
tal illnesses (SMI), i.e., those entailing serious limitations
in social functioning and requiring coordinated profes-
sional care [19]. As well as behavior that would be likely
to seriously disrupt the group, the exclusion criteria
were having severe cognitive impairments and having in-
sufficient knowledge of the Dutch language.
Participants were recruited from six Community Mental
Health Teams (CMHTs) serving people with severe and
persistent mental illness at Bavo Europoort, a mental
health institution in the greater Rotterdam area in the
Netherlands, a conurbation with approximately 1.2 million
inhabitants. Each sub-region of about 150,000 inhabitants
was served by a Community Mental Health Team and an
Assertive Community Treatment Team (ACT).
Clients of the CMHTs who met the eligibility criteria
were identified and asked by their clinicians to partici-
pate in IMR. From the start, most participants in IMR
also participated in the pilot study.
The following activities were undertaken to prepare
for the implementation of IMR in this institution: to visit
Prof. Mueser and colleagues and to see IMR in practice,
a study trip was made to Dartmouth Psychiatric Re-
search Center New Hampshire, USA; an implementation
plan was drawn up; plenary meetings were held with all
outpatient clinicians at the institute and members of the
clients council; a steering committee, an implementation
committee and an education committee were estab-
lished; translated handouts and workbooks were edited;
a two-day training was held for 18 trainers and six su-
pervisors; four supervision groups were established, a
master class was given by Susan Gingerich, one of the
creators of IMR; six IMR groups were started; and this
pilot study was started.
Interventions
In essence, IMR is a structured training consisting of 11
modules, practitioner guides and handouts for participants.
The 11 modules are 1.) Recovery Strategies, 2.) Practical
Facts about Mental Illness, 3.) the Stress-Vulnerability
Model, 4.) Building Social Support, 5.) Using Medication
Effectively, 6.) Drug and Alcohol Use and Treatment Strat-
egies, 7.) Reducing Relapses, 8.) Coping with Stress, 9.)
Coping with Problems and Persistent Symptoms, 10.) Get-
ting Your Needs Met in the Mental health System, and 11.)
Health for You.
The original American text had been translated into
Dutch; where necessary, it was slightly adapted to the
Dutch context. The IMR-training was given at the par-
ticipating institute in a group format with weekly ses-
sions. For the pilot, all six IMR groups completed the
whole curriculum.
During the first module, which was the only module
that was done individually, the participants decided
which personal goals they wanted to work on during the
program. For half of each 90-minute session, some par-
ticipants worked on their goals in the group. During the
other half of each session, all participants worked with
the help of the handouts on the subjects of the modules.
Each IMR group was guided by two professional
trainers (ten psychiatric nurses, one psychologist and
one psychiatrist), who used 1.) motivation-enhancement
strategies such as conveying confidence and exploring
the pros and cons of change; 2.) educational strategies
(psycho education) such as breaking down information,
interactive teaching, and checking for understanding;
and 3.) cognitive-behavioral techniques such as shaping,
modeling and role-play. Peer-group support and coping
& social skills training are integral to IMR. Homework
assignments are provided.
Whether all different aspects of the intervention were
actually administered is part of the fidelity, which was
assessed for feasibility (see below).
Objectives
Objectives and hypotheses of the main study
The aim of the RCT is to compare the effectiveness of
the IMR training program with that of care as usual
(CAU) for patients with SMI. Our hypotheses are in-
spired by Mueser’s conceptual framework [1, 10]. The
first primary hypothesis of the main study is that IMR +
CAU (where IMR is offered in group format) leads to
better illness management and to fewer symptoms and
relapses than CAU only. The second primary hypothesis
is that, compared to CAU only, IMR + CAU leads not
only to better “subjective” recovery (perceived recovery,
sense of purpose, and personal agency), but also to bet-
ter “objective” recovery (role and social functioning).
We also have four secondary hypotheses. 1.) We ex-
pect the cost-utility of IMR + CAU to be better than that
of CAU. 2.) We expect better illness management (i.e.,
getting more insight, better coping, more social support,
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less addiction and better service engagement) to lead to
fewer symptoms and relapses. Testing this will help us ex-
plore the working mechanisms of IMR. (3) The third hy-
pothesis we will test is that, in terms of Mueser [1], better
“distal outcomes” (i.e., recovery) result from a combin-
ation of better “proximal outcomes” (i.e., better illness
management and fewer symptoms and relapses) and pro-
gress on personal goals. (4) Finally, we expect that any im-
provement resulting from IMR +CAU will be associated
with the fidelity with which IMR is implemented.
Objectives of the pilot study
Our primary objectives concern the assessment of the
feasibility of implementing the IMR training program on a
broader scale at Bavo Europoort. As a satisfactory power
level would be achieved only if we included enough pa-
tients in the planned RCT—we planned 200—we exam-
ined whether the institute would succeed in recruiting
sufficient participants for the six IMR groups planned.
The institution’s willingness to implement IMR in the long
term would depend largely on clients’ and clinicians’ satis-
faction with IMR, on which the effectiveness of the pro-
gram would clearly have a bearing.
Our secondary objectives regard the assessment of the
quality with which IMR is implemented. Because fidelity is
considered to be associated with better outcomes [20–23],
secondary objectives were to evaluate whether it was feas-
ible to apply the 11 modules of IMR with satisfactory fidel-
ity in the Dutch context and to set up an adequate
infrastructure for trainers’ training and supervision, which
is a precondition for implementing IMR with good fidelity.
Further secondary objectives for the pilot study were to ex-
plore the duration of the program and dropout from it.
The dropout percentage would give an indication of the
number of completers of the intervention that could be ex-
pected in the main study. We also wanted to explore client
characteristics related to dropout.
Outcome measures for the main study
Illness management and illness outcomes
The primary outcome measure of the main study is the
client version of the IMRS [10–12, 24]. One of the sec-
ondary outcome measures is the clinician-rated IMRS
[10–12, 24]. The items of these two IMR scales mainly
concern aspects of illness management and illness out-
comes. Each of the two scales includes 15 items scored
on a 5-point scale [11, 12]. Research on the IMR Scales
indicates that internal consistency is moderate, that two-
week test-retest reliability is high, and that the scales
have convergent validity [24–28]. This supports the use
of the IMR Scales in assessing illness management and
recovery in people with severe mental illness.
Additional illness-management scales
Given the limited number of items in the IMR scales,
the main study will also assess illness management using
other validated and more comprehensive scales as sec-
ondary outcome variables, assessing coping, social sup-
port, treatment compliance, insight into illness, and
problems with alcohol and drugs. To measure these
topics, we will use the respective instruments: the Cop-
ing Self-Efficacy Scale (CSES) [29], the Multidimensional
Scale of Perceived Social Support (MSPSS) [30], the Ser-
vice Engagement Scale (SES) [31], the Insight Scale (IS)
[32], and one item (item 24) of the Addiction Severity
Index (ASI) [33, 34].
Illness outcomes: symptoms and relapses
The secondary outcomes on illness-management out-
comes are symptoms, health complaints and functional
limitations, and relapses. These topics will be measured
with the Brief Symptom Inventory (BSI) [35–37] and the
EQ-5D [38], with the number of relapses being opera-
tionalized as the number and duration of hospital admis-
sions and the number of emergency-department visits.
Recovery
In Mueser’s conceptual framework [1], the concept of
recovery is differentiated into subjective recovery and
objective recovery. We will assess subjective recovery as
secondary outcome variables using a generic personal
recovery scale, and by using four measures to assess in-
ternal stigma, self-esteem and life-goals: The Mental
Health Recovery Measure (MHRM) [39, 40] (authorized
Dutch translation [41, 42]); the Internal Stigma of
Mental Illness (Ismi) [43]; one item of the Quality of Life
section of the Cumulative Needs for Care Monitor
(CNCM) [44]; and the Self-Esteem Rating Scale-Short
Form (SERS-SF) [45]. In line with Muesers’ conceptual
framework, we view improving on personal goals as a
mediator variable between illness self-management and
recovery [1]. We will measure improving on personal
goals with Granholm’s Goals Template [46]. Objective
recovery will be assessed using the Social Functioning
Scale [47].
Cost-utility
The number and duration of outpatient treatment con-
tacts and inpatient days will be calculated on the basis of
their cost in Euros, and are related with changes in qual-
ity of life measured by the EQ-5D [38]. Cost-utility can
be calculated by transforming scores on the EQ-5D into
quality-adjusted life-years (QALYs) [48].
IMR model fidelity
The researchers will determine model fidelity using the
IMR Fidelity Scale [49], the IMR General Organizational
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Index (GOI) [2], and the Illness Management and Re-
covery Treatment Integrity Scale (IT-IS) [50].
Outcomes
Outcome measures for the pilot study
Assessment of our primary objectives resulted in our
primary feasibility outcomes, which regard 1) the num-
ber of participants, 2) clients’ and clinicians’ satisfaction
with IMR, and 3) the effectiveness of the program. As-
sessment of our secondary objectives resulted in our sec-
ondary feasibility outcomes, which regard 1) fidelity, 2)
setting up an infrastructure for education and supervi-
sion, 3) drop-out and completion, and 4) program dur-
ation. We also explored the completers’ characteristics.
Like program duration, participants’ recruitment, drop-
out and completion (i.e., participant numbers, participant
characteristics related to dropout, and their reasons for
dropout) are all measured by using monitoring data from
the institute’s internal reports and registrations and by
having interviews with clinicians. Completion of the pro-
gram was defined as attendance of 70 % of the program
sessions; non-completers were termed “dropouts from
treatment”. Participants' and clinicians’ satisfaction with
IMR were assessed in interviews with participants and cli-
nicians. The infrastructure for trainers’ training and super-
vision was assessed in interviews with clinicians. The
principal researcher (BJR) and one co-author (MB) carried
out the semi-structured interviews. These two authors cat-
egorized and summarized data according to the topics of
the interviews.
The fidelity of implementation of IMR per group was
measured on the IMR Fidelity Scale [49]. The IMR Fi-
delity Scale is a scale to assess the degree of implemen-
tation of the IMR model. It consists of 13 items, each of
which is rated on a five-point scale and each of which is
behaviorally anchored; a score of five indicates full im-
plementation. The other scale points represent an in-
creasing degree of implementation [51]. The total score
is the mean of all item-scores. Per group, fidelity meas-
urement took almost a day, and was carried out by the
principal researcher on the day of one of the last ses-
sions. It consisted of semi-structured interviews with
participants and the two trainers, plus observation of
one session, and checking forms.
The effectiveness of IMR with regard to illness man-
agement and illness-management outcomes was mea-
sured with the Illness Management and Recovery Scale
patient self-score version; and with the lllness Manage-
ment and Recovery Scale clinician-rated version. Simi-
larly, the effectiveness of IMR with regard to Recovery
was measured with the Recovery Markers Questionnaire
[RMQ] [52], a free-standing 24-item self-report subscale
of the Recovery Enhancing Environment Measure (REE),
which has a 5-point agreement-response scale ranging
from “strongly agree” to “strongly disagree”. The scale
has high internal and face validity [53, 54]. Measuring
improvement on recovery is a secondary outcome meas-
ure of the main study.
Sample size
For the pilot study we could include most people who
intended to participate in the six IMR groups (N = 81).
We did baseline measurements and gathered socio-
demographic data on these participants.
Feasibility criteria
Our primary feasibility criterion was whether the institute
was able to recruit a sufficient number of participants for
the six IMR groups planned for the pilot study. According
to the IMR Fidelity Scale, the maximum number of partic-
ipants in a group is eight [49]. We therefore needed 48
participants. Making allowance for some dropout, we thus
aimed to recruit about ten people per group: 60 in total.
We wanted to establish how many clients had to be asked
to participate in IMR for this number to be reached. Our
second primary feasibility criterion was the satisfaction of
most participants and clinicians with IMR. The third was
to achieve significant results on our effectiveness-related
outcome measures.
Our first secondary feasibility criterion was that the in-
stitute could achieve total scores on the IMR Fidelity
Scale of ≥ 4.0, which is considered to reflect good fidelity
[51, 55]; in other earlier research on IMR, cut-off scores
for good or high IMR fidelity were > 3.7 [6], > 3.8 [56].
In their review, McGuire et al. reported a weighted mean
of 4.05 on fidelity for “all studies” (SD = .93) [5]. We also
wished to identify the aspects of fidelity (as shown in
item-scores) in which quality of implementation of IMR
had to improve. Additionally, we tested whether the in-
stitute had successfully created a good infrastructure for
trainers' supervision and training, our criteria for success
being the institute's ability to fulfill its intention of com-
pleting a two-day training for all trainers, and of super-
vising trainers for two hours a week. The IMR review [5]
refers to five studies in which training of trainers had
taken two days [1, 51, 55, 57, 58]. While three other
studies reported that training took 40 h [59], five days
[8] and 48 h [6] respectively, the latter had involved only
50 % of the trainers.
On the assumption that dropout from treatment
should be minimized, we wanted to establish how much
dropout from treatment we could expect in the main
study. We set no prior targets for the number of com-
pleters. The review of IMR studies refers to a median
dropout rate from IMR of 24 % and a range of dropout
rates from 18 % to 30 %; this review also refers to a me-
dian of 63 % completers and a weighted mean of 36 %,
with a range of 15 %-86 % [5]. Of the four earlier RCTs,
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one reported an IMR drop-out rate of 21 % [6], and a
second reported that 46 % of the participants assigned
to the program attended fewer than half of the IMR ses-
sions [7]. A third reported 5 % drop-out [8], but partici-
pants of this study had been selected “on the basis of
consistent attendance of prior (non-IMR) services, and
training and consultation focused heavily on consumer
engagement” [5]. The fourth RCT reported that drop-
out from IMR—defined as participating in less than half
the scheduled groups—was 72 % [9]. Our fourth second-
ary feasibility criterion that would enable us to plan the
main study properly is whether the duration of IMR was
predictable. According to the review of IMR studies [5],
9-12 months is a usual length for a program consisting
of one session per week; in three earlier RCT studies in
which IMR was also applied in a weekly group format,
IMR lasted for 8-11 months [6] and 9 months [8, 9].
Statistical analysis
We used a paired sample t-test to measure the effective-
ness of IMR (one group pre- and post- measurement)
on the IMR-scale client version, the IMR-scale clinician
version, and the RMQ. Chi square tests and independent
samples t-tests were used to test differences between
completers’ and non completers’ baseline characteristics.
Ethical aspects
The study protocol, information brochure and informed
consent form for the RCT were approved by the Dutch
Union of Medical-Ethical Trial Committees for mental
health organizations (registration number of the Dutch Na-
tional Trial Register NTR 5033 http://www.trialregister.nl,
CCMO-no NL38605.078.12).
The pilot study was a naturalistic study in which the
researchers observed and recorded the implementation
of IMR in the institute in its natural setting over a pro-
longed period, while interfering as little as possible with
the subjects and the implementation process. Conducted
by researchers employed at Bavo Europoort’s internal
research and development department, it was imple-
mented as a routine program evaluation under the regu-
lar quality control for care-innovation projects with a
local scope. As its objective was not to gain generalizable
medical scientific knowledge, it could not be defined as
medical research according to the rules of the Dutch
Central Committee on Research Involving Human Sub-
jects (CCMO) [60] under the Dutch Medical Research
Involving Human Subjects Act (WMO) [61]. For this
reason, no external medical ethical permission was re-
quested. The study was approved by the medical director
of the institute.
Potential participants were provided with information
on the program evaluation; participation in the evalu-
ation was not a mandatory requirement for participation
in the IMR program. Participants were asked individu-
ally whether they consented to be interviewed, and were
asked their permission for the observation of one IMR-
session per team for purposes of fidelity measurement.
The outcomes were reported anonymously.
Results
Participant flow
Influx and outflux of participants in IMR
In the recruitment phase, 167 clients were asked by their
clinicians to participate in IMR. Eighty-one who signed
up to participate in IMR (49 %) were included in the
study and had a first measurement; 73 of the 81 started
with the first module (eight dropouts), which was done
individually with one clinician. Fifty-one of these 73 par-
ticipants started with the second module (22 dropouts),
which, like the remaining modules, was given in group
format. Forty of the 51 attended at least 70 % of all ses-
sions (11 dropouts) and were thus considered to be
completers (see Fig. 1). Dropout from the time of com-
mitment to participate in IMR was thus 51 %; counted
from the start of real participation, it was 45 %. Mea-
sured from the point at which clients had committed
themselves to participating, dropout from treatment was
highest between modules one and two, which coincided
with the transition from the individual format to the
group format. With regard to the 41 non-completers,
their clinicians reported the following causes of dropout:
worsening of psychiatric condition (16), lack of motiv-
ation (7), not liking being in a group (5); problems with
the time at which the session was held (4), personal rea-
sons such as moving away from the area, language prob-
lems, concentration problems or finding IMR too hard
to do (7); and unknown (2).
After completing IMR, the participants were assessed
for the second time. In a deviation from our original
protocol, a sudden reduction in the research team meant
we could not conduct follow-up measurements of the
non-completers.
Recruitment
The pilot study started at the beginning of 2009. The
period for recruiting participants and for baseline mea-
surements lasted from April 2009 to January 2010. The
period of second measurements lasted from April 2010
to December 2010. Data collection took place in 2009,
2010 and 2011. Data-analysis took place in 2012, 2014
and 2015.
Baseline data
Participants’ characteristics
Forty-eight participants in the pilot study (N = 81) were
men (59 %). On average, participants were aged 42.
Forty percent lived alone, 39 % had attended only lower
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education, 9 % had income from employment, 28 % had
not been born in the Netherlands, 54 % had psychiatric
problems that had started over 10 years before, and 56 %
had been hospitalized at least once. Seventy-three per-
cent had been diagnosed as having a psychotic disorder,
54 % had a length of treatment of more than five years,
and 20 % had previously been hospitalized for longer
than one year, see Table 1.
Outcomes and estimation
Table 2 gives an overview of the feasibility objectives,
outcome measures, feasibility criteria and outcomes of
the IMR pilot study.
A. Primary feasibility outcomes
Number of participants The institute succeeded in run-
ning the six IMR groups planned, all of which completed
the whole curriculum and which, between them, suc-
ceeded in recruiting 81 participants of 167 people assessed
for eligibility, so more than the 60 participants needed; see
“influx and outflux of participants in IMR,” above.
Satisfaction On the day of the last session of their IMR
group, or some days later, 20 completers were interviewed
(50 % of all completers), 17 in group interviews and three
individually. All twelve clinicians who had trained the six
IMR groups were interviewed individually.
Completers were very positive about IMR. Most of all,
they wanted to achieve the following: to obtain know-
ledge (13 respondents); to increase insight (13 respon-
dents); the contact with fellow patients (peer-contact) (9
respondents); to work on personal goals (8 respondents);
and to learn coping skills (also named 8x).
All IMR-trainers were positive about IMR; some said
that they saw changes in individual clients. They appreci-
ated the content of the training, adding, for example, that
it was very structured and “nice and fun to give.” Trainers
appreciated the recovery vision of IMR. Some thought
that participants learn most by practicing social skills such
as assertiveness. They appreciate it if there is a lot of inter-
action in the group and if role-play and exercises can be
done according to the topics of the modules. They
thought that peer contact helps and that participants are
motivated to meet each other. Some trainers observed that
participants adopted coping mechanisms from each other.
Most trainers said that, as safety in the group is an import-
ant condition for people to open up, they preferred to
have a “closed group,” i.e., no rolling admissions.
Effectiveness Completers showed a significant improve-
ment on the IMR Scale clinician version (N = 36); and
Fig. 1 Flow Diagram Pilot study IMR
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Table 1 Characteristics at baseline of completers of IMR versus non- completers
Total N = 81 Completers
N = 40
Dropouts from
IMR N = 41
χ2 (df = 1) p OR 95 % CI
gender male 48 59 % 19 29 4.53 .033* 2.67 [1.07, 6.67]
female 33 41 % 21 12
living situation
living alone 32 40 % 19 13 2.18 .139 0.48 [0.18, 1.28]
living with others 34 42 % 14 20
missing 15 18 %
education level
low 31 39 % 14 17 0.81 .369 1.59 [0.58, 4.36]
middle + high 30 37 % 17 13
missing 10 24 %
native country
born in Holland 42 52 % 22 20 0.47 .492 0.70 [0.25, 1.95]
immigrant 23 28 % 10 13
missing 16 20 %
diagnosis
psychotic disorders 59 73 % 31 28 0.58 .446 0.68 [0.25, 1.85]
All other diagnoses 21 26 % 9 12
missing 1 1 %
start of problems
<10 years ago 20 25 % 8 12 0.55 .457 1.50 [0.51, 4.38]
>10 years ago 44 54 % 22 22
missing 17 21 %
length of treatment
<5 years 17 21 % 6 11 1.42 .234 2.01 [0.63, 6.39]
>5 years 44 54 % 23 21
missing 20 25 %
number of admissions
None 12 15 % 6 6 0.04 .837 0.88 [0.25, 3.13]
≥1 45 56 % 21 24
missing 24 29 %
length hospitalization
<1 year 37 46 % 18 19 0.01 .928 1.06 [0.33, 3.41]
>1 year 16 20 % 8 8
missing 28 35 %
source of income
employment, unemployment
or invalidity benefit
46 57 % 27 19 4.26 .039* 0.29 [0.09, 0.97]
social security benefit 17 21 % 5 12
missing 18 22 %
M (SD) N M (SD) N M (SD) t (df ) Cohen’s d
Age 81 100 % 42.35 (10.12) 40 44.03 (8.70) 41 40.71 (11.20) 1.49 (75) .140 0.33 [0.11, 0.77]
IMR-scale client version at
baseline
66 82 % 3.36 (0.42) 36 3.46 (0.39) 30 3.24 (0.42) 2.21 (64) .031* 0.55 [1.04, 0.05]
70 86 % 3.09 (0.50) 37 3.22 (0.44) 33 2.94 (0.53) 2,41 (68) .019* 0.58 [1.06, 0.10]
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also on the RMQ (N = 31). Completers did not show a
significant improvement on the IMR Scale client version
(N = 33), see Table 3.
B. Secondary feasibility outcomes
Fidelity The mean (SD) total fidelity score of the six
groups was 4.0 (.20), which meets the stated objective
of ≥ 4.0. The median (IQR) was 3.9 (.35). Three groups
had overall good fidelity, with total scores on the IMR
Fidelity Scale [49] of 4.0, 4.2 and 4.2. But three groups
had moderate fidelity, all with total scores of 3.8. Eight
items with scores ranging from 4.2 to 5.0 reflected good
implementation: “Number of People in a Session or
Group,” “Program Length,” “Comprehensiveness of the
Curriculum,” “Provision of Educational Handouts,” “IMR
Goal Setting,” “Motivation-Based Strategies,” “Educational
Techniques” and “Cognitive-Behavioral Techniques”. Four
aspects were implemented poorly in all groups: “Involve-
ment of Significant Others,” “Coping-Skills Training,” “Re-
lapse-Prevention Training” and “Behavioral Tailoring for
Medication.” The greatest variance was on item 7 regard-
ing “IMR Goal Follow-up,” which was implemented well
in 3 groups and not implemented well in 3 groups; the
items score ranged from 1–5, see Table 4.
Due to a ceiling effect, the differences between groups
perceived for some items in the quality of implementa-
tion during observation of one session per team were
reflected only partly in the scores of the fidelity scale. In
particular, this concerned items 8 (motivation-based
strategies), 9 (educational techniques), and 10 (cognitive-
behavioral techniques). Variance in fidelity appeared to
be related to differences in the trainers’ skills and their
experience in guiding groups. This was reflected particu-
larly in their ability to practice social and coping-skills
training, role-play, relapse-prevention training, and mo-
tivational strategies.
Infrastructure for education and supervision By set-
ting up a system for the supervision and training of the
trainers, the institute successfully created an infrastruc-
ture for implementing IMR on a broader scale. The
Table 1 Characteristics at baseline of completers of IMR versus non- completers (Continued)
IMR-scale clinician version
at baseline
Recovery Markers
Questionnaire [RMQ]
62 77 % 12.4 (5.76) 33 12.5 (5.55) 29 12.3 (6.1) 0.14 (60) .890 0.04 [0.54, 0.46]
Mdn/IQR Mdn/IQR Mdn/IQR U p r
GAF 79 98 % 50/10 39 55/10 40 50/10 591 .058 -.21 [-0.42, 0.01]
*significant p < .05
Table 2 Overview of IMR pilot study (main feasibility objectives and outcomes)
Objectives Outcome measures Feasibility criteria Outcomes
1 To include sufficient
participants
Monitoring; interviews 60 people 81 people included of 167, assessed for eligibility
(49 %); sufficient for 6 IMR groups
2 Clients’ and clinicians’
satisfaction with IMR
Interviews Satisfaction of most participants
and clinicians with IMR
Completers and trainers:(very) positive about IMR
3 IMR outcome (pre-post
design)
IMR Scale client
version
(Mueser et al. 2004)
IMR Scale clinician
version
(Mueser et al. 2004)
RMQ (Ridgway et al.
2003)
Significant results on our outcome
measures
IMRS clinician version (p < 0.001, d = 0.84)a
IMRS client version (p = 0.063; d = 0.41)
RMQ (p = 0.003, d = 0.52)a.
4 Satisfactory fidelity IMR fidelity scale
(Mueser et al. 2009)
Total scores on the fidelity scale
of at least 4.0.
Total score (six groups): Mean (SD) = 4.0 (0.20)
Three groups: total scores≥ 4.0
Three groups: total scores < 4.0
5 Trainers' education and
supervision
Interviews Two-day training and Supervision
of two hours per week
Two-day course before start of the pilot; Supervision
bi-weekly for two hours; Additional training 2 x per
year for 4 h.
6 Dropout from IMR Monitoring; interviews Exploration, no targets set Dropout from IMR of 51 %
7 Duration of the IMR-
program
Monitoring; interviews Predictable; 9–12 months M = 12.7 months, SD = 3.14
aSignificant improvement in completers
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trainers were experienced clinicians (mostly psychiatric
nurses, but also a psychologist and a psychiatrist), who
1.) all received a two-day course in teaching IMR before
the start of the pilot and 2.) attended supervision once
every two weeks for two hours. Twice a year since the
start of the pilot, all IMR trainers have come together for
a morning or afternoon of additional booster training.
Dropout and completion Measured from the point at
which clients committed themselves to participation,
dropout from IMR was 51 %; measured from the mo-
ment of actual participation, it was 45 %. The number of
participants per IMR group at the start ranged from six
to twelve, and the number in the last sessions from three
to nine. Four groups were “closed groups” (no new in-
flux at dropout); two groups had “rolling admissions”.
Defined as > 70 % participation, completion of IMR was
49 %; measured from the moment of actual participation,
it was 55 %. If program completion is defined as having re-
ceived all IMR modules [5], the completion rate was 44 %;
measured from the moment of actual participation, it was
49 % (see Participant Flow, above, and Fig. 1).
Duration While the average length required per mod-
ule lay between three and four 90-min sessions, it
could vary between groups between one and eight
sessions, according to the module and the group’s
preference or specific challenges. The durations of the
IMR training for the six groups were 8, 11, 12, 13, 15
and 17 months (M = 12.7 months, SD = 2.87).
Completers’ characteristics at baseline Significantly
more women than men completed IMR, and, at baseline,
completers scored significantly better than non-completers
on the client and clinician versions of the IMR scale.
An association between completion and source of in-
come showed that those in employment, those receiving
unemployment benefit and those receiving invalidity
benefit had a significantly greater chance of completing
IMR than those receiving social security benefit. To us,
this suggests that people who dropped out were at a
greater distance from everyday working life, and possibly
have more problems in maintaining structured and so-
cial activities than completers. There were no significant
differences between completers and non-completers on
the baseline scores of the Recovery Markers Question-
naire (RMQ) or the Global Assessment of Functioning
scale (GAF). Neither were there associations between
completion with living situation, education level, native
country, diagnosis, period of start of problems, length
Table 3 Effectiveness of IMR completers (one group pre- and post- measurement; paired sample t-test)
N M (SD) pre M (SD) post t Df p d 95 % CI
IMR-scale client version 33 3.47 (0.39) 3.66 (0.50) 1.93 32 .06 0.41 [-0.08, 0.90]
IMR-scale clinician version 36 3.21 (0.44) 3.59 (0.48) 4.73 35 <.001 0.84 [0.36, 1.32]
RMQ 31 12.23 (5.61) 14.94 (4.84) 3.19 30 .003 0.52 [0.01, 1.02]
Table 4 Fidelity-scores on the IMR-fidelity scale of the six IMR groups
Group A B C D E F M (SD) Mdn (IQR)
Item
1 # of people in a Session or Group 4 5 5 5 4 5 4.7 (.52) 5 (.75)
2 Program Length 5 5 5 5 5 5 5 (0) 5 (0)
3 Comprehensiveness of the Curriculum 5 5 5 5 5 5 5 (0) 5 (0)
4 Provision of Educational Handouts 5 5 5 5 5 5 5 (0) 5 (0)
5 Involvement of Significant Others 3 1 3 3 3 3 2.7 (.82) 3 (0)
6 IMR Goal Setting 5 5 5 5 5 5 5 (0) 5 (0)
7 IMR Goal Follow-up 5 4 2 5 1 2 3.2 (1.72) 3 (2.75)
8 Motivation-Based Strategies 5 4 4 5 5 5 4.7 (.52) 5 (.75)
9 Educational Techniques 5 5 5 5 5 5 5 (0) 5 (0)
10 Cognitive-Behavioral Techniques 5 4 4 5 4 4 4.3 (.52) 4 (.75)
11 Coping Skills Training 3 2 2 4 3 2 2.7 (.82) 2.5 (1)
12 Relapse-Prevention Training 2 2 3 1 3 3 2.3 (.82) 2.5 (1)
13 Behavioral Tailoring for Medication 2 2 2 2 1 3 2 (.63) 2 (0)
Mean fidelity score per group 4.2 3.8 3.8 4.2 3.8 4.0 4.0 (.20) 3.9 (.35)
Median fidelity score (IQR) 5 (2) 4 (3) 4 (2) 5 (1) 4 (2) 5 (2)
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of treatment, number of admissions, and length of
hospitalization, see Table 1.
Discussion
Interpretation
As the primary objectives of this pilot study concerned
the feasibility of implementing the IMR training pro-
gram on a broader scale, we measured the following: 1.)
whether the institute had succeeded in recruiting suffi-
cient participants for the planned six IMR groups, 2.)
clients’ and clinicians’ satisfaction with IMR, and 3.) the
effectiveness of the program.
That the institute could recruit 81 IMR participants to
the pilot study from the 167 people assessed for eligibil-
ity means that we exceeded our feasibility criterion of
60. This suggests that a good number of clients is inter-
ested in this treatment. It also supports the feasibility of
getting sufficient participants for the RCT, although
recruiting for an RCT is probably harder than recruiting
for a pilot study with no control group.
The satisfaction of the completers interviewed and of
all clinicians was very good. However, as we measured
this only at follow-up, we could not measure change
over time, and as we did not interview people who
dropped out, we know only that 49 % of all participants
were satisfied with IMR.
IMR was effective for completers on the IMR-scale
clinician version, with a large effect-size d = 0.84, and on
the RMQ, with a medium effect size (d = 0.52), but there
was no significant improvement on the IMR-scale client
version (d = 0.41). However, a limitation of this pilot
study is our deviation from the original protocol: due to
a sudden reduction in the research team, we could not
conduct follow-up measurements or interview the non-
completers; neither did we have a control group. We
nevertheless conclude that our institute appears to have
a sufficiently firm support base for implementing IMR
on a broader scale, and that this contributes to the feasi-
bility of an RCT.
The secondary objectives of the pilot study were to im-
plement IMR with satisfactory fidelity, to create a sufficient
infrastructure for the trainers’ education and supervision,
to explore program duration, and to explore dropout.
With regard to the RCT, we see it as an advantage
that, due probably to sufficient trainer education and
supervision, the institute successfully established six
IMR groups in this pilot period whose average total fi-
delity score on the IMR Fidelity Scale was 4.0. Therefore
our feasibility criterion of ≥ 4.0 was met. We also see it
as very useful that our item scores helped us identify the
aspects of implementation of IMR that the institute
must improve to achieve total scores ≥ 4.0 for all groups.
Because the results of the interviews suggested that vari-
ance in fidelity is related to the differences in the
trainers’ professional skills, this gives input for further
education and supervision. We have decided to add the
IT-IS scale [50] to the RCT, as it focuses on measuring
clinicians’ skills related to fidelity.
One of our feasibility criteria for a good infrastructure
for education and supervision was to give all 12 trainers
two days’ training, and to supervise them for two hours
per week. A two days’ training was indeed achieved for
all 12 trainers, and the trainers had eight hours of sup-
plemental training in one year. These 24 h were more
than the length of training in five studies in McGuire’s
review, but less than in three other studies (one of which
had involved only 50 % of the trainers) (see above). Al-
though the institute had intended to provide supervision
once weekly, productivity requirements meant that
trainers could attend supervision only once every two
weeks for two hours throughout the duration of the pilot
study and thereafter. This was more intensive than in
one RCT, which reported monthly supervision [6], but
less intensive than in another, which reported weekly
supervision [8]. Because, in one year, the institute suc-
cessfully achieved a good average total fidelity score of
4.0, we suggest that fidelity may be further improved by
continuing such education and supervision, especially if
the focus lies on aspects of fidelity that most need im-
provement (see above). Although our results on dropout
from IMR were worse than those reported in the review
on IMR [5], and also than those in one earlier RCT on
IMR [6], they do not appear to be worse than the num-
bers in two other RCTs [7, 9], even though the overall
results are not entirely comparable: in our study, drop-
out is defined as < 70 % participation. But with regard to
the planned RCT, we conclude that if no measures are
taken to reduce it, allowance should be made for sub-
stantial dropout from IMR.
McGuire et al. [5] report a median completion rate of
63 % with a range of 15 %-86 %. If we adopt his defin-
ition of program completion—having received all IMR
modules, which in our study would mean a completion
rate of 44 %— our result falls well within this range.
But as McGuire et al. said with regard to the studies
they reviewed, we feel that the dropout and completion
rates found in our study “leave much room for improve-
ment.” For the RCT, we plan to recommend clinicians
and managers to pay attention to this aspect and to take
various measures including the use of a good dropout
protocol. Our baseline analysis of completers’ and non-
completers’ characteristics also suggest that, to reduce
dropout from IMR, special attention is required by male
participants, people who receive social security benefit,
and people who score lower on the IMR scales at base-
line. And although “intention to treat” will be used in
the RCT, we have decided that a ratio of 3:2 will be used
for randomization. This will enable us to include more
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participants in the experimental condition, and will pro-
vide enough power for secondary analysis of effective-
ness for completers.
The different durations of the IMR-training—which
ranged from 8 to 17 months (M = 12.7 months, SD =
2.87)—were on average somewhat longer than the 9 to
12-month range mentioned in McGuire’s review, and
also longer than those in three earlier RCT studies in
which IMR was applied in a weekly group format [6, 8, 9].
The durations of 15 and 17 months of two groups are a
particular cause for concern. For properly feasible plan-
ning of the RCT, we have therefore asked the institute to
try to maximize IMR length at around 12 months. This is
because if we plan the first follow-up measurement
after one year in the RCT, an IMR length of longer
than 1 year would mean that participants would not
have completed the whole curriculum, which might
be seen as a disadvantage.
Conclusions
The main objective of this pilot study was to assess the
feasibility of conducting an RCT. Our results with regard
to the recruitment of sufficient participants, to clients’
and clinicians’ satisfaction with IMR, and to the effect-
iveness of the program all suggest the feasibility of our
primary objectives for this pilot study, which regard
implementing the IMR-training program on a broader
scale at Bavo Europoort.
The feasibility of an RCT is also suggested by the results
with regard to our secondary objectives regarding the qual-
ity of implementation: to implement IMR with satisfactory
fidelity, to set up a proper infrastructure for education and
supervision, and to achieve an acceptable dropout percent-
age and a predictable program duration. If the institute is
willing to follow our recommendations on recruitment,
improving fidelity, training and supervision, and duration
of the program, feasibility might even be greater.
Generalizability
A precondition for generalizability of the feasibility
found in this pilot study is that other institutions have
the same drive to create a comparable infrastructure for
implementing and sustaining IMR, and also have com-
parable potential for doing so: this is because imple-
menting six IMR groups from scratch required a
considerable effort on the part of the institute.
This pilot study has limitations that impair generaliz-
ibility of some results. As stated above: it was only for
completers—49 % of all participants—that we could
measure effectiveness and satisfaction. As the RCT was
planned for implementation in the same institution, and
as the pilot study was a naturalistic study, interfering as
little as possible with the subjects and the implementa-
tion process, good generalizability of the other results of
the pilot study to the RCT was probably to be expected.
But although recruitment in the IMR pilot went well, we
suppose that recruiting for an RCT will be harder.
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